Say what the record supports.
We distinguish specifications, test results and release decisions from clinical interpretation.
For research, professional, and investigational evaluation only. No exosome product is FDA-approved for therapeutic use in humans.
About B&H Bio
Built around what can be documented.
B&H Bio organizes product evaluation around source records, stated methods and lot-level traceability rather than unsupported clinical or superiority claims.
Operating position
Conservative by design.
We do not represent exosome products as FDA-approved for therapeutic use, and we do not present research compounds as products for human consumption.
- Documentation over promisesClaims should not outrun the underlying record.
- Product-specific reviewSpecifications and limitations stay attached to the material they describe.
- Explicit approval boundariesExternal communication, ordering and business actions remain owner-gated.
Keep the lot connected.
A result is useful only when it can be reconciled to the product under evaluation.
Leave unsupported claims out.
No unverified approval, efficacy, superiority, disease or outcome language.
Documentation available
Start with the records.
Tell us what you are evaluating. We will match the request to the relevant current-batch documentation.